Bitopertin Phase 3 Claim Unverified Despite Replicated Phase 2 PPIX Dose Response

Disc Medicine's Bitopertin Redeemed by Positive Phase 3 Data

Disc Medicine announced positive Phase 3 trial results for its lead asset, bitopertin, in erythropoietic protoporphyria (EPP), a rare disease causing pain upon light exposure. This readout marks a significant redemption for the drug, which was previously rejected by the FDA in February. The trial successfully met all primary and secondary endpoints, demonstrating a reduction in the key biomarker PPIX and a significant increase in the time patients could spend in the light. These favorable outcomes position Disc Medicine to pursue another FDA application for bitopertin.

• Regulatory Redemption: Disc Medicine's bitopertin has achieved a significant turnaround, reporting positive Phase 3 data after an unexpected FDA rejection earlier in February. This prior rejection for erythropoietic protoporphyria (EPP) had surprised the biopharma industry, especially given the drug had previously received a Commissioner’s National Priority Voucher, making the current successful trial results a crucial validation for the company.
• Key Efficacy Outcomes: The late-stage trial demonstrated compelling efficacy, meeting all its primary and secondary endpoints. Specifically, bitopertin led to a notable reduction in PPIX, a critical biomarker associated with EPP. Furthermore, patients treated with bitopertin experienced a significant increase in the duration they were able to spend exposed to light, directly addressing a core symptom of the rare disease.
• Pathway to Re-submission: The robust positive data from the Phase 3 trial sets Disc Medicine on a clear path for a renewed regulatory submission. The comprehensive success across all measured endpoints provides a strong foundation for another application to the FDA, aiming to secure approval for bitopertin as a treatment for erythropoietic protoporphyria.

Addressing Key Challenges in Erythropoietic Protoporphyria Treatment

Current treatment approaches for erythropoietic protoporphyria improve light tolerance and quality of life but leave persistent photosensitivity and substantial liver-related risk. Management remains largely supportive and, in advanced hepatopathy, requires complex transplantation with risk of recurrence and mortality.

• Persistent phototoxicity despite therapy: Avoiding sunlight exposure remains central to management, and even with supportive measures including ursodeoxycholic acid and antioxidants S-adenosylmethionine and vitamin E, probable persistent erythropoietic protoporphyria-related solar dermatopathy was reported at 4 years of age in a managed case. In trials, afamelanotide increased duration of sun exposure without pain and improved quality of life, with tolerance to natural sunlight up to 24 times longer than prior to therapy in an early study, yet phototoxic reactions still occurred (77 vs. 146, P=0.04 in the European Union study).

• Limited evidence base for afamelanotide: Early efficacy data came from five EPP patients in an open-label study with a sustained-release subcutaneous implant of 20 mg afamelanotide administered twice with a 60-day interval, requiring confirmation by a large-scale trial due to the limited number of patients enrolled and the design being an open-label study. Later multicenter, randomized, double-blind, placebo-controlled trials used subcutaneous implants containing 16 mg of afamelanotide every 60 days (a total of five implants in the European Union study [74 patients] and three in the U.S. study [94 patients]) over respective 180-day and 270-day study periods, with median pain-free time of 69.4 hours vs. 40.8 hours in the placebo group (P=0.04) after 6 months in the U.S. study and 6.0 hours vs. 0.8 hours (P=0.005) after 9 months in the European Union study.

• Common liver abnormalities with risk of advanced hepatopathy: In 322 patients with erythropoietic protoporphyria or X-linked protoporphyria, liver chemistries were available for 235 patients and 132 (56.2%) had abnormalities, mostly mild, with abnormal liver enzymes associated with higher erythrocyte protoporphyrin levels. Eleven patients had advanced protoporphyric hepatopathy, and only 3.4% had protoporphyric hepatopathy, with most requiring a transplant; patients with XLP were more likely to develop liver-related complications compared to EPP.

• High burden of liver-related interventions and mortality: In the same cohort, 54 (16.8%) underwent cholecystectomy, 8 (2.5%) had a liver transplant, 4 (1.2%) had a bone marrow transplant, and 8 (2.5%) died, with at least 4 deaths caused by liver failure due to protoporphyric hepatopathy, 2 were complications of bone marrow transplant, and 1 from HCC, which developed in a patient with EPP without cirrhosis. Of the deaths, 62.5% were attributable to liver disease.

• Transplantation complexity, recurrence and biliary risk: Severe protoporphyric hepatopathy results in liver failure, requiring both liver and bone marrow transplantation as a life-saving procedure and to correct the underlying enzymatic defect, respectively. A 20-year-old man who underwent split liver transplantation using a right trisegment and caudate lobe graft for EPP-induced liver failure succumbed to early relapse of EPP and subsequent, intractable, late-onset bile leakage from the cut surface of segment 4, with EPP recurrence most likely creating a high-risk situation for bile leakage from the non-communicating bile ducts of segment 4; split liver transplantation should preferably be avoided and sequential BMT should be considered by a multidisciplinary team as soon as hepatic reserve deterioration becomes evident.

• Tolerability profile requiring ongoing monitoring: Afamelanotide had an acceptable side-effect and adverse-event profile with adverse events mostly mild and serious adverse events not thought to be related to the study drug, with no drug-related serious adverse events reported in the phase III trial CUV039. Commonly occurring adverse reactions included headache and implant-site reactions, and except for two low-grade pain episodes, patients in the early study recorded no phototoxic events past Day 4 of treatment.

Bitopertin's Pivotal Phase 3 Design and Endpoints in EPP

Key trials in erythropoietic protoporphyria (EPP) span prospective cohort studies, observational registries, and interventional evaluations focused on sunlight tolerance, phototoxic reactions, and quality of life. Designs vary from single-center longitudinal follow-up to multicenter observational and diary-based validation studies, with endpoints capturing time outdoors, reaction severity, and disease-specific patient-reported outcomes.

Bitopertin's Potential to Reshape the EPP Treatment Landscape

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are inborn errors of heme biosynthesis that cause elevated circulating levels of metal-free protoporphyrin and phototoxicity, characterized by excruciating phototoxic attacks after exposure to visible light. Afamelanotide, an α-melanocyte-stimulating hormone analogue melanocortin 1 receptor agonist, is the only approved treatment for protoporphyria and leads to increased light tolerance and improved quality of life. Published real-world data confirm this benefit: in the Swiss EPP cohort (n = 39) maximum phototoxic burn tolerance time increased from median 10 min (IQR 5-20) before treatment to median 180 min (IQR 120-240) under treatment, in the Austrian EPP cohort (n = 20) from median of 15 minutes (IQR 10-25) to median of 250 minutes (IQR 120-300) with EPP QoL score increasing from median of 11.11 (IQR 3.03-19.44) to median of 79.17 (IQR 75.00-97.22), and in a US cohort of 29 patients with protoporphyria receiving ≥2 afamelanotide implants from 12.5 min (IQR, 5-20) to 120 min (IQR, 60-240) after treatment (p < 0.001), with no improvements in median levels of metal-free erythrocyte protoporphyrin, plasma protoporphyrin, or liver biochemistries.

Dersimelagon (MT-7117: dersimelagon phosphoric acid) is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin. In a randomized, placebo-controlled, phase 2 trial (NCT03520036), 102 patients (93 with erythropoietic protoporphyria and 9 with X-linked protoporphyria) 18 to 75 years of age were randomly assigned in a 1:1:1 ratio to receive placebo or dersimelagon at a dose of 100 or 300 mg once daily for 16 weeks, with the primary end point of change from baseline to week 16 in the time to the first prodromal symptom associated with sunlight exposure. Of the patients who underwent randomization, 90% completed the treatment period. The least-squares mean difference from placebo in the change from baseline to week 16 was 53.8 minutes in the 100-mg dersimelagon group (P = 0.008) and 62.5 minutes in the 300-mg dersimelagon group (P = 0.003). The results also suggest that quality of life improved in patients receiving dersimelagon as compared with placebo. The most common adverse events that occurred or worsened during treatment were nausea, freckles, headache, and skin hyperpigmentation. Proof of concept was obtained in phase 2 clinical studies on EPP and XLP, and compound MT-7117 is currently in clinical trials for the treatment of EPP, X-linked protoporphyria (XLP), and systemic sclerosis (SSc).

The investigational pharmacotherapies dersimelagon and bitopertin could offer benefits such as treatment options for children and prevention of some of the associated disease complications. The currently available trial data on dersimelagon and bitopertin suggests treatment effects in EPP as compared to placebo control groups, although safety and efficacy of dersimelagon and bitopertin need to be further characterized. In a departmental series, 10 patients with EPP and iron deficiency took daily dosages of 330 mg of ferrous fumarate for two months; after 2 months seven patients had increased PPIX level compared to baseline, two had decrease, one remained unchanged, with a rise in ferritin, improvement in blood hemoglobin in four of the five patients with anemia at baseline, and a small transiently elevation in plasma alanine transaminase concentration during supplementation.

Bitopertin's Redemption: A New Era for Protoporphyria Treatment

The recent positive Phase 3 results for bitopertin in erythropoietic protoporphyria (EPP) mark a pivotal moment for patients suffering from this debilitating rare genetic disorder. EPP, characterized by severe light sensitivity and painful phototoxic reactions due to the accumulation of protoporphyrin IX (PPIX), currently lacks approved disease-modifying therapies. Bitopertin, an orally available small molecule, acts as an inhibitor of the glycine transporter 1 (GLYT1), thereby directly targeting the underlying pathophysiology by reducing PPIX biosynthesis. The successful trial demonstrated significant reductions in PPIX levels and a notable increase in patients' ability to tolerate light exposure, addressing a critical unmet need. This outcome is particularly significant given the drug's prior regulatory setback, positioning it for a renewed FDA application.

Strategically, these data strongly support bitopertin's potential as a first-in-class oral therapy, offering a novel approach to managing EPP and potentially X-linked protoporphyria (XLPP) by directly mitigating PPIX accumulation. This could redefine the standard of care, moving beyond symptomatic management to a disease-modifying strategy.

However, several considerations warrant attention. While promising, the specifics surrounding the previous regulatory rejection will be under scrutiny during the upcoming review, requiring clear communication on how those concerns have been addressed. Furthermore, comprehensive long-term safety and efficacy data, particularly regarding sustained improvements in quality of life and potential impact on hepatobiliary complications, will be crucial for broad clinical adoption and payer acceptance. The reported incidence of dizziness in earlier studies, while generally mild, also warrants careful monitoring in a chronic treatment setting.

Bitopertin's success offers a beacon of hope for EPP patients and underscores the potential of targeting heme biosynthesis pathways. Its journey through regulatory review will be closely watched as it aims to establish a new therapeutic paradigm.